Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial (Q89936669)
Jump to navigation
Jump to search
scientific article published on 25 February 2020
Language | Label | Description | Also known as |
---|---|---|---|
English | Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial |
scientific article published on 25 February 2020 |
Statements
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial (English)
Jaclyn A Smith
Michael M Kitt
Alyn H Morice
Surinder S Birring
Lorcan P McGarvey
Mandel R Sher
Yu-Ping Li
Wen-Chi Wu
Zhi Jin Xu
David R Muccino
Anthony P Ford
Protocol 012 Investigators
25 February 2020